C646 是一種histone acetyltransferase抑制劑,抑制p300,無細胞試驗中Ki為400 nM,相比于其它乙酰轉移酶,優(yōu)先作用于p300。C646 可誘導細胞周期阻滯、細胞凋亡與自噬。
C646 Chemical Structure
CAS: 328968-36-1


| 相關靶點 | HAT MYST GNAT p300/CBP | 點擊展開 |
|---|---|---|
| 相關產品 | MG149 WM-1119 CPTH2 JQAD1 YF-2 EML 425 WM-3835 Acetyl-Histone H3 (Lys27) Antibody [L2M16] | 點擊展開 |
| 相關化合物庫 | 激酶抑制劑庫 FDA藥物庫 天然產物庫 已知活性藥物庫-I 高選擇性抑制劑庫 | 點擊展開 |
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息(PMID) |
|---|---|---|---|---|---|
| Kasumi-1 | Growth inhibition assay | 10, 25 and 50 μM | 0, 24, 48, 72 h | cellular growth and colony formation were dramatically suppressed upon C646 treatment. | 23390536 |
| SKNO-1 | Growth inhibition assay | 10, 25 and 50 μM | 0, 24, 48, 72 h | cellular growth and colony formation were dramatically suppressed upon C646 treatment. | 23390536 |
| WM983B | Function assay | 10 μM and 20 μM | 24 h | a dose-dependent decrease in the protein levels of cyclins A and E, accompanied by an increased expression of p53 and its downstream effector p21 | 23698071 |
| WM35 | Function assay | 10 μM and 20 μM | 24 h | a dose-dependent decrease in the protein levels of cyclins A and E, accompanied by an increased expression of p53 and its downstream effector p21 | 23698071 |
| 1205Lu | Function assay | 10 μM and 20 μM | 24 h | a dose-dependent decrease in the protein levels of cyclins A and E, accompanied by an increased expression of p53 and its downstream effector p21 | 23698071 |
| Raw246.7 | Function assay | 1, 5, 10, 15, 20, 25, or 30 μM | 16 h | results in significant inhibition of LPS and IFNγ induced NF-κB promoter activity at 15 μM or higher concentrations | 26718586 |
| KATO III | Function assay | 10 μM | 6 h | C646 treatment significantly reduced the levels of histone H3 acetylation in both GC cells and normal gastric epithelial cells (P<0.05) | 29075795 |
| BGC-823 | Function assay | 10 μM | 6 h | C646 treatment significantly reduced the levels of histone H3 acetylation in both GC cells and normal gastric epithelial cells (P<0.05) | 29075795 |
| MGC-803 | Function assay | 10 μM | 6 h | C646 treatment significantly reduced the levels of histone H3 acetylation in both GC cells and normal gastric epithelial cells (P<0.05) | 29075795 |
| SGC-7901 | Function assay | 10 μM | 6 h | C646 treatment significantly reduced the levels of histone H3 acetylation in both GC cells and normal gastric epithelial cells (P<0.05) | 29075795 |
| MKN45 | Function assay | 10 μM | 6 h | C646 treatment significantly reduced the levels of histone H3 acetylation in both GC cells and normal gastric epithelial cells (P<0.05) | 29075795 |
| GES-1 | Function assay | 10 μM | 6 h | C646 treatment significantly reduced the levels of histone H3 acetylation in both GC cells and normal gastric epithelial cells (P<0.05) | 29075795 |
| SH-SY5Y | Function assay | 20?μM | 24 h | Co-treatment with 20 μM C646 suppressed the effect of TSA treatment on Alox15 mRNA expression by 65.7% | 29235036 |
| NE-4C cells | Function assay | 0-5 μM | high glucose induced increases of H4K5ac and H4K5/8/12/16ac levels in NE-4C cells are inhibited by addition of a selective CBP/p300 inhibitor C646 in a dose-dependent way (from 0 to 5 μM) | 30114346 | |
| BL21-CodonPlus(DE3)-RIL | Function assay | 10 mins | Inhibition of FLAG-tagged p300 (1195 to 1673 residues) (unknown origin) expressed in competent Escherichia coli BL21-CodonPlus(DE3)-RIL cells using histone H4 substrate incubated for 10 mins by scintillation counting method in presence of [14C]acetyl-CoA, IC50 = 9 μM. | 26701186 | |
| BL21(RIL)-DE3 | Function assay | 10 mins | Inhibition of synthetic VMA-tagged p300 (1287 to 1652 residues) (unknown origin) expressed in Escherichia coli BL21(RIL)-DE3 cells using H4-15 peptide substrate incubated for 10 mins by radiometric filter binding assay in presence of [14C]acetyl-CoA, IC50 = 1.6 μM. | 26701186 | |
| BL21(RIL)-DE3 | Function assay | 10 mins | Inhibition of synthetic VMA-tagged p300 (1287 to 1652 residues) (unknown origin) expressed in Escherichia coli BL21(RIL)-DE3 cells using H4-15 peptide substrate incubated for 10 mins by radiometric filter binding assay in presence of [14C]acetyl-CoA, Ki = 0.4 μM. | 26701186 | |
| 點擊查看更多細胞系數據 | |||||
| 產品描述 | C646 是一種histone acetyltransferase抑制劑,抑制p300,無細胞試驗中Ki為400 nM,相比于其它乙酰轉移酶,優(yōu)先作用于p300。C646 可誘導細胞周期阻滯、細胞凋亡與自噬。 | ||
|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | C646是一種組蛋白乙酰轉移酶抑制劑,抑制p300,Ki為400 nM,選擇性作用于其他乙酰轉移酶。10 μM C646在體外抑制86% p300。C646是傳統(tǒng)的,可逆p300抑制劑。C646(25μM)作用于細胞,降低組蛋白 H3 和 H4 乙?;?,且廢除TSA誘導的乙?;?。C646(20μM)作用于對雄激素敏感的閹割性前列腺癌細胞系,通過干擾AR和NF-kB通路,而誘導細胞凋亡。C646作用于小鼠細胞,抑制全部H3K4me3動態(tài)乙?;揖植繖M跨啟動子和誘導基因的起始位點,從而干擾RNA聚合酶II相互作用和這些基因的激活。 | |||
|---|---|---|---|---|
| 激酶實驗 | 放射性檢測 | |||
| 使用直接放射性測定法測定對假定的p300 HAT抑制劑的IC50值。反應在20 mM HEPES (pH 7.9)中進行,包含5 mM DTT, 80μM EDTA, 40μg/ml BSA, 100μM H4-15, 和 5 nM p300。加入在一個濃度范圍內的假定抑制劑,DMSO 濃度保持不變(<5%)。反應在30°C 下溫育10分鐘, 然后加入1:1 12C-acetyl-CoA 和 14C-acetyl-CoA 的混合物到 20 mM,開始反應。在30°C下進行10分鐘后,使用14% SDS (w/v) 淬火。所有濃度按一式兩份篩選。跑膠,洗滌,干燥,暴露于PhosphorImager板上,對產生的Ac-H4-15進行量化,得到IC50值。 | ||||
| 細胞實驗 | 細胞系 | C3H10T1/2 | ||
| 濃度 | ~25 μM | |||
| 孵育時間 | 1 到3小時 | |||
| 方法 | 在小鼠細胞中測定組蛋白乙酰化。C3H10T1/2小鼠成纖維細胞在含10% FCS的DMEM 培養(yǎng)基中 在37°C下含6% CO2的環(huán)境中生長。鋪滿培養(yǎng)物在含0.5% FCS 的DMEM 培養(yǎng)基中靜置18-20小時,然后再處理。使用如下化合物處理細胞:TSA (10 ng/ml [33 nM]), C646 (25 μM), C37 (25 μM)。使用如下濃度的抗體: 總H3 (1:10000); H4K12ac (1:2500)。兔anti-H3K9ac(1:10000)抗體內部產生。通過酸提取從細胞中分離組蛋白,經SDS和酸-尿素聚丙烯酰胺凝膠電泳分離,并通過免疫印跡分析。 | |||
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Western blot | α-c-Myc Cyclin A1/2 / Cyclin E2 / p53 / p21 H3K27Ac |
|
28630312 | |
| Immunofluorescence | BRD4 / p300 |
|
28630312 | |
| 體內研究(In Vivo) | ||
| 體內研究活性 | 弱滅絕訓練后,C646立即注入到ILPFC,增強恐懼消退記憶的整合。C646處理脊髓,衰減機械痛和熱痛覺過敏,伴隨著抑制COX-2表達。 | |
|---|---|---|
| 動物實驗 | Animal Models | 小鼠 |
| Dosages | 每種情況下2×0.75 μl 注射體積, 1.5 μg, 處理 超過2分鐘 | |
| Administration | 注入 ILPFC | |
|
| 分子量 | 445.42 | 分子式 | C24H19N3O6 |
| CAS號 | 328968-36-1 | SDF | Download C646 SDF |
| Smiles | CC1=CC(=C(C=C1C)[N+](=O)[O-])C2=CC=C(O2)C=C3C(=NN(C3=O)C4=CC=C(C=C4)C(=O)O)C | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 11 mg/mL ( (24.69 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內溶解配方 現配現用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內配方計算器 | |||||
動物體內配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯系Selleck);
體內配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯系到我們。我們會在24小時內盡快聯系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
I am planning to conduct IP studies in mice with it, any specific vehicle that you can recommend to me?
回答:
It can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 1 mg/ml as a clear solution, and should be ok for i.p. injection.